The Pfizer-BioNTech COVID-19 vaccine was well tolerated and demonstrated 100% efficacy and robust antibody responses in a phase 3 clinical trial in 2,260 children aged 12-15, the vaccine’s makers announced today

The companies plan to ask the Food and Drug Administration to expand the vaccine’s emergency use authorization to this age group based on the study data, which they said found no COVID-19 cases in the vaccinated group compared with 18 in the placebo group. The EUA currently applies to individuals age 16 and older. 

The companies last week launched a trial evaluating the vaccine’s safety and efficacy in children aged 6 months to 11. 
 

Related News Articles

Headline
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices is holding an emergency meeting this afternoon on the Johnson…
Headline
The monoclonal antibody therapy REGEN-COV (casirivimab with imdevimab) reduced the risk of symptomatic COVID-19 in household contacts of people with SARS-CoV-2…
Headline
The Food and Drug Administration and Centers for Disease Control and Prevention today jointly recommended a pause in the use of Johnson & Johnson’s…
Headline
Pfizer today said it is seeking an amended emergency use authorization for its COVID-19 vaccine, requesting that the Food and Drug Administration allow…
Headline
Nearly 80% of prekindergarten through 12th grade teachers, school staff and child care workers had received at least their first COVID-19 shot by April, the…
Headline
Leaders from Henry Ford Health System and the Islamic Center of America discuss their collaboration to increase vaccinations in the Muslim community around…